Evaluation of microRNA 92a Expression and Its Target Protein Bim in Colorectal Cancer.
| Autor: | Zaki A; Department of Clinical Pathology, National Cancer Institute, Cairo University, Egypt., Fawzy A; Department of Clinical Pathology, National Cancer Institute, Cairo University, Egypt., Akel SY; Department of Clinical Pathology, National Cancer Institute, Cairo University, Egypt., Gamal H; Department of Surgical Oncology, National Cancer Institute, Cairo University, Egypt., Elshimy RAA; Department of Clinical Pathology, National Cancer Institute, Cairo University, Egypt. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Asian Pacific journal of cancer prevention : APJCP [Asian Pac J Cancer Prev] 2022 Feb 01; Vol. 23 (2), pp. 723-730. Date of Electronic Publication: 2022 Feb 01. |
| DOI: | 10.31557/APJCP.2022.23.2.723 |
| Abstrakt: | Background: Colorectal cancer is one of the most commonly diagnosed cancers and leading causes of malignancy-related deaths all over the world. MicroRNAs (miRNAs) can regulate more than 60% of human genes, including tumor-stimulating, and -suppressor genes. Therefore, they can promote cancer development and affect risk of malignancy. miR-92a overexpression in CRC enhances tumor proliferation, invasion, and metastasis through downregulating different pro-apoptosis proteins including Bim. This study aimed to assess the role of plasma miR-92a as non-invasive marker in CRC patients, outline correlation between plasma miR-92a and serum Bim, and determine their correlations with clinicopathological parameters in CRC and adenoma patients. Methods: A total of 54 newly diagnosed CRC patients, 15 colonic adenoma patients, and 15 age- and sex-matched control subjects were recruited in this study. Plasma miR-92a was assayed by TaqMan qRT-PCR and serum Bim was measured by ELISA. Results: Statistically significant overexpression of serum miR-92a was observed in CRC patients as compared to adenoma and control groups (p<0.001 each) and lower serum Bim in CRC patients as compared to adenoma and control groups (p=0.001, p <0.001 respectively). The ROC curve analysis showed excellent AUC for plasma miR-92a in discriminating CRC from control (AUC=0.994), and adenoma (AUC=0.993) groups with highest diagnostic performance in discriminating CRC from controls (at cutoff 1.43, sensitivity 98.1%, specificity 93.9%), and adenoma patients (at cutoff 1.78, sensitivity 92.6%, specificity 93.3%). The diagnostic performance in discriminating early from late CRC was good (at cutoff 15, AUC=0.641, sensitivity 61.2%, specificity 80%). A significant negative correlation was evident between plasma miR-92a and serum Bim both in adenoma and CRC groups (P<0.001 for both). Higher plasma miR-92a expression (r=0.275, p=0.044) and lower serum Bim (r=-0.299, p=0.028) were found to be correlated with late CRC stages. Conclusion: Circulating miR-92a and Bim could be promising, non-invasive diagnostic and prognostic biomarkers in CRC. . |
| Databáze: | MEDLINE |
| Externí odkaz: |
|